Skip to search formSkip to main contentSkip to account menu

Ag 3340

Known as: AG3340, Ag-3340, Prinomastat/AG 3340 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

prinomastat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Nonselective matrix metalloproteinase but not tumor necrosis factor-α inhibition effectively preserves the early critical colon anastomotic integrity
BackgroundIncreased matrix metalloproteinase (MMP) activity has been implicated in the pathogenesis of colorectal anastomotic… 
2009
2009
Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia–ischemia
Highly Cited
2008
Highly Cited
2008
Delayed administration of a matrix metalloproteinase inhibitor limits progressive brain injury after hypoxia-ischemia in the neonatal rat
BackgroundHypoxia-ischemia (H-I) can produce widespread neurodegeneration and deep cerebral white matter injury in the neonate… 
2005
2005
Inhibition of Membrane Type-1 Matrix Metalloproteinase by Cancer Drugs Interferes with the Homing of Diabetogenic T Cells into the Pancreas*
We have discovered that clinically tested inhibitors of matrix metalloproteinases can control the functional activity of T cell… 
2001
2001
Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit.
To determine the ocular pharmacokinetics, physiological and histological effects of prinomastat (a matrix metalloprotease… 
2001
2001
Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model.
2000
2000
The Effect of Prinomastat (AG3340), a Synthetic Inhibitor of Matrix Metalloproteinases, on Posttraumatic Proliferative Vitreoretinopathy
In a search for a pharmacologic adjuvant in the management of posttraumatic proliferative vitreoretinopathy (PVR), we… 
2000
2000
AG-3340 (Agouron Pharmaceuticals Inc).
: Agouron Pharmaceuticals is developing AG-3340 (prinomastat), the lead compound in a series of structurally related… 
1998
1998
Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations
Oral administration of AG3340, a novel metalloprotease (MMP) inhibitor, suppresses the growth of human colon adenocarcinoma (COLO… 
1997
1997
Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
Matrix metalloproteinases are a family of zinc-containing proteases that degrade extracellular matrix and basement membranes… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)